Skip to main content

Systemic Bio

ApplicationHouston, TX, USAFounded 2022· One of 381 Application companies tracked by AMPulse

Develops 3D bioprinted vascularized organ-on-a-chip models (h-VIOS platform) using hydrogels and human cells for preclinical drug testing, reducing reliance on animal models and accelerating drug discovery timelines.

CEO / Founder
Taci Pereira
Team Size
11-50
Stage
Defunct
Total Funding
$15M
Latest Round
Seed
Key Investors
3D Systems

Technology & Products

Key Products

VitalHeal (bioprinted wound patch), h-VIOS™ platform for evaluating the safety of antibody-drug conjugates (ADCs)

Technological Advantage

VERIFIED: Technology derived from 3D Systems' decades of additive manufacturing expertise and acquisition of Allevi, providing high-throughput, reproducible bioprinting capabilities. DEFENSIBLE: Protected by 3D Systems' patent portfolio in additive manufacturing, though specific bioprinting patents not detailed.

Differentiation

Value Proposition

Provides physiologically relevant human tissue models that improve predictive accuracy in drug testing, potentially reducing drug development costs and time-to-market by enabling earlier failure detection and optimization.

How They Differentiate

Offers 10x greater build volume and up to 10x higher resolution than typical bioprinters, enabling production-scale manufacturing of organ models vs. BICO's cost-efficient tools and Organovo's scaffold-free tissues.

Market & Competition

Target Customers

Pharmaceutical and biotechnology companies

Industry Verticals

Pharmaceuticals; Biotechnology; Medical Research

Competitors

Hyku Biosciences

Growth & Milestones

Growth Metrics

Raised $15 million in seed funding; grew to a team of 30; built a 15,000-square-foot facility; could produce 6,000 vascularized hydrogels per month.

Major Milestones

Founded in 2022 with $15M seed funding; Opened 15,000 sq ft state-of-the-art laboratory in Houston in 2023; Won SLAS 2025 Innovation Award; Ceased operations in 2024

Notable Customers

Partnerships with major pharmaceutical firms.

https://systemic.bio

Why this company matters

Systemic Bio addresses the gap between traditional cell culture and animal models by producing 3D bioprinted vascularized tissues that better mimic human physiology. Its h-VIOS platform uses hydrogels and human cells to create organ-on-a-chip models for preclinical drug testing, aiming to improve predictive accuracy and enable earlier detection of drug failures.

The core technology is material extrusion bioprinting, derived from 3D Systems' additive manufacturing expertise and the acquisition of Allevi. Systemic Bio claims at least 10 times greater build volume and up to 10 times higher resolution than typical commercial bioprinters, allowing scalable production of complex tissues. Key products include the VitalHeal wound patch and h-VIOS models for evaluating antibody-drug conjugate safety.

Target customers are pharmaceutical and biotechnology companies seeking more physiologically relevant testing platforms. The company has a collaboration with United Therapeutics on lung scaffold development. It raised $15 million in seed funding from parent company 3D Systems, built a 15,000-square-foot facility in Houston, and won the SLAS 2025 Innovation Award before ceasing operations in 2024.

Systemic Bio's competitive position was anchored by 3D Systems' patent portfolio and its ability to produce up to 6,000 vascularized hydrogels per month. It differentiated from Organovo's scaffold-free tissues and BICO's cost-efficient tools through production-scale bioprinting. The company's closure raises questions about the commercial viability of bioprinted organ models for drug testing.